KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Shares Outstanding (2020 - 2026)

AbCellera Biologics filings provide 7 years of Shares Outstanding readings, the most recent being $303.9 million for Q1 2026.

  • Quarterly Shares Outstanding rose 1.87% to $303.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $303.9 million through Mar 2026, up 1.87% year-over-year, with the annual reading at $2.1 million for FY2019, N/A changed from the prior year.
  • Shares Outstanding hit $303.9 million in Q1 2026 for AbCellera Biologics, up from $299.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $303.9 million in Q1 2026 and bottomed at $284.5 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $292.8 million, with a median of $293.6 million recorded in 2024.
  • The largest annual shift saw Shares Outstanding rose 5.02% in 2022 before it rose 1.31% in 2025.
  • AbCellera Biologics' Shares Outstanding stood at $285.8 million in 2022, then grew by 1.41% to $289.8 million in 2023, then increased by 1.86% to $295.2 million in 2024, then grew by 1.31% to $299.0 million in 2025, then rose by 1.65% to $303.9 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Shares Outstanding are $303.9 million (Q1 2026), $299.0 million (Q3 2025), and $298.7 million (Q2 2025).